Barclays
BEAM icon

Barclays’s Beam Therapeutics BEAM Stock Holding History

Barclays’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.51M Buy
143,399
+73,180
+104% +$2.04M ﹤0.01% 2238
2026
Q2 		$2.41M Buy
70,219
+22,581
+47% +$682K ﹤0.01% 2238
2026
Q1 		$1.14M Sell
47,638
-278,540
-85% -$7.73M ﹤0.01% 2679
2025
Q4 		$9.04M Buy
326,178
+12,551
+4% +$320K ﹤0.01% 1755
2025
Q3 		$7.61M Sell
313,627
-370,972
-54% -$7.38M ﹤0.01% 1877
2025
Q2 		$11.6M Buy
684,599
+524,553
+328% +$9.13M ﹤0.01% 1470
2025
Q1 		$3.13M Sell
160,046
-117,973
-42% -$3.09M ﹤0.01% 2288
2024
Q4 		$6.89M Buy
278,019
+94,805
+52% +$2.42M ﹤0.01% 1875
2024
Q3 		$4.49M Buy
183,214
+101,387
+124% +$2.62M ﹤0.01% 2180
2024
Q2 		$1.92M Sell
81,827
-4,849
-6% -$119K ﹤0.01% 2182
2024
Q1 		$2.86M Sell
86,676
-161,708
-65% -$5.04M ﹤0.01% 2269
2023
Q4 		$6.76M Buy
248,384
+50,737
+26% +$1.26M ﹤0.01% 1847
2023
Q3 		$4.75M Buy
197,647
+53,115
+37% +$1.42M ﹤0.01% 1342
2023
Q2 		$4.61M Buy
144,532
+28,903
+25% +$938K ﹤0.01% 1397
2023
Q1 		$3.54M Sell
115,629
-5,990
-5% -$236K ﹤0.01% 1779
2022
Q4 		$4.76M Buy
121,619
+12,883
+12% +$577K ﹤0.01% 1668
2022
Q3 		$5.18M Buy
108,736
+78,267
+257% +$4.46M 0.01% 1142
2022
Q2 		$1.18M Buy
30,469
+15,444
+103% +$614K ﹤0.01% 2219
2022
Q1 		$859K Buy
+15,025
New +$985K ﹤0.01% 2526

Other funds holding BEAM

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
D.A. Davidson & Co
D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Barclays's BEAM Position: Q3 2026 in Review

Barclays increased its Beam Therapeutics (BEAM) stake by 104% in Q3 2026, buying an estimated $2.04M and bringing the position to 143,399 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Barclays first reported a position in BEAM in Q1 2022 and has held it in 19 quarters since. The position peaked at $11.6M in Q2 2025. 96 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Barclays held 143,399 shares of Beam Therapeutics worth $3.51M as of Q3 2026.
  • Barclays bought 73,180 Beam Therapeutics shares in Q3 2026, an estimated $2.04M.
  • Beam Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2238 holding.
  • Barclays first reported a position in Beam Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Beam Therapeutics position peaked at $11.6M in Q2 2025.
  • 96 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.